Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 15;40(42):6114–6124. doi: 10.1016/j.vaccine.2022.08.024

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Published by Elsevier Ltd.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — Antibodies against SARS-CoV-2 spike and mRNA-based vaccine formulations in vaccinees’ sera. Sera from BNT162b2 (left column) or mRNA-1273 (right column) vaccinees collected at baseline (n = 10 for BNT162b2 and n = 10 for mRNA-1273 groups), 18.9 days (arithmetic mean ± 2.4 SD) after the prime (n = 10 for BNT162b2 and n = 10 for mRNA-1273 groups) and 19.3 days (arithmetic mean ± 3.9 SD) after the boost (n = 10 for BNT162b2 and n = 10 for mRNA-1273 groups), were tested for IgG antibodies against SARS-CoV-2 full-length spike (A and B), BNT162b2 mRNA LNPs (C and E), and mRNA-1273 mRNA LNPs (D and F) by ELISA. Dotted line represents the limit of detection (LOD) of the assay. Statistically significant differences between post-prime/post-boost vs baseline antibody levels are shown. One-way ANOVA with Tukey’s multiple comparisons test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.